

Nitric Oxide-donors

NCX 667 and NCX 1660

Two of Nicox's new generation nitric oxide donors targeting intraocular eye pressure IOP reduction , NCX 667 and NCX 1660, are currently in the formulation and testing stage with Re-Vana's EyeLief™ technology (topical and biodegradable drug delivery System) in the the research collaboration agreement signed in October 2017. Depending on the release profile observed for these molecules with this technology in nonclinical animal models of ocular pharmacokinetics, their development could be continued and / or it might be decided to test d `other molecules with this same technology.

NCX 667 demonstrates robust, dose-dependent lowering of intraocular pressure in various normotensive and

hypertensive ocular models

NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO)

NCX 667 is a lead molecule among the Company's future generation of stand-alone NO-donors which are designed to optimize NO dosing and can be used alone or in combination with existing standard-of-care drugs, as either ophthalmic solutions or extended release formulations, to enable robust intraocular pressure (IOP)-lowering in patients with open-angle glaucoma or ocular hypertension.

Preclinical results obtained in rabbits and dogs with normal IOP and in rabbit and non-human primate models of ocular hypertension demonstrate rapid and sustained IOP lowering compared to vehicle following repeated dosing with no signs of tachyphylaxis or ocular discomfort.